Qiming U.S. Healthcare Fund II, L.P. - 29 Jun 2021 Form 4 Insider Report for Elevation Oncology, Inc. (ELEV)

Reporting relationship: 10%+ Owner
Issuer ticker: ELEV
Reported as of: 29 Jun 2021
Net transaction value: +$5,000,000
SEC form: 4
Accepted by SEC: 01 Jul 2021, 19:45:43 UTC
Prior SEC filing: 24 Jun 2021
Next SEC filing: 28 Jul 2021
Source filing: View source filing
Reporting owner signature: Qiming U.S. Healthcare Fund II, L.P., by Qiming U.S. Healthcare GP II, LLC, its General Partner

Key filing fact

Qiming U.S. Healthcare Fund II, L.P. filed Form 4 for Elevation Oncology, Inc. (ELEV) on 01 Jul 2021.

Key facts

This page summarizes Qiming U.S. Healthcare Fund II, L.P.'s Form 4 filing for Elevation Oncology, Inc. (ELEV).
5 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 01 Jul 2021, 19:45.

Change

Previous filing in this sequence was filed on 24 Jun 2021.
Current net transaction value: +$5,000,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ELEV transaction

Common Stock

Conversion of derivative security

Transaction value: $0
Shares: +1,656,577
Change %
Price: $0.000000
Shares after: 1,656,577
Date: 29 Jun 2021
Ownership: Direct
Footnotes: F1, F2

ELEV transaction

Common Stock

Conversion of derivative security

Transaction value: $0
Shares: +401,065
Change %: +24%
Price: $0.000000
Shares after: 2,057,642
Date: 29 Jun 2021
Ownership: Direct
Footnotes: F1, F2

ELEV transaction

Common Stock

Purchase

Transaction value: $5,000,000
Shares: +312,500
Change %: +15%
Price: $16.00^*
Shares after: 2,370,142
Date: 29 Jun 2021
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ELEV transaction Derivative

Series A Preferred Stock

Conversion of derivative security

Transaction value: $0
Shares: -7,000,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 29 Jun 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,656,577
Exercise price
Footnotes: F1, F2

ELEV transaction Derivative

Series B Preferred Stock

Conversion of derivative security

Transaction value: $0
Shares: -1,694,730
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 29 Jun 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 401,065
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The Shares of the Issuer's Preferred Stock automatically converted on a 4.225582-for-one basis into the number of shares of the Issuer's Common Stock in shown in column 7 immediately upon the closing of the Issuer's initial public offering, and had no expiration date.

Footnote F2

The securities are directly held by Qiming U.S. Healthcare Fund II, L.P. ("Qiming"). Qiming U.S. Healthcare GP II, LLC ("Qiming GP") is the General Partner of Qiming, and may deem beneficial ownership of shares held by Qiming, and includes Gary Rieschel, as Managing Member of Qiming GP, and Mark McDade, Co-Founder, and Partner of Qiming, that each may share voting and investment power of the shares held by Qiming.